Combination renin-angiotensin system blackade in hypertension  by Doulton, Timothy W.R. & Macgregor, Graham A.
Kidney International, Vol. 68 (2005), pp. 1898–1904
LETTERS TO THE EDITOR
Combination
renin-angiotensin system
blockade in hypertension
To the Editor: Wolf and Ritz recently reviewed the use
of an angiotensin-converting enzyme inhibitor (ACEI)
and angiotensin receptor blocker (ARB) combination,
and commented upon an additive effect on blood pres-
sure (BP) in some subjects receiving the combination
compared to monotherapy [1].
A recent meta-analysis of the effectiveness of an
ACEI-ARB combination in hypertension showed a 4/3
mm Hg fall in BP compared with ACEI or ARB
monotherapy [2]. Although this difference was statis-
tically significant, it is questionable whether it really
represents an additive effect because the studies upon
which this analysis was based predominantly used lower
doses of short-acting ACEIs, with measurement of BP
at trough or over 24 hours. Given that ARBs are gen-
erally longer-acting than ACEIs, it is not surprising that
an additive effect was seen. In the only study where a
long-acting ACEI (trandolapril) was given, there was
no additive effect of an ARB on BP [3]. Other studies
have shown that an ACEI-ARB combination may not
be more efficacious than monotherapy when the latter is
given at maximal dosage and at the correct frequency [4,
5]. Clearly, further studies need to be done using much
higher doses of ACEIs, with twice daily dosing for most
ACEIs, and measurement of BP at peak in addition to
trough.
None of the studies, except perhaps COOPERATE,
have really been of sufficient duration and size to deter-
mine the potential dangers of this treatment [3]. We agree
with the authors that it would be premature to recom-
mend the widespread use of an ACEI-ARB combination
until further safety studies have been done.
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CD4+CD25+ regulatory T
cells: A new treatment option
in glomerulonephritis
To the Editor: Future perspectives on the treatment
of glomerulonephritis (GN) were the subject of a re-
cent review article by Javaid and Quigg [1]. We totally
agree with the authors that new treatment options in GN
are needed. The authors mentioned diverse new aspects
of treatment, including antigen-specific therapy by us-
ing double-stranded DNA molecules, as well as blocking
effector systems by targeting complement factor C5 or
TNF-a receptor with antibodies. But still, the results are
not satisfying. Recently, our group provided compelling
evidence that CD4+CD25+ T cells, so called regulatory
T cells (Treg), could be a new therapeutic treatment op-
tion in GN. Treg were recently described to play a pivotal
role in the maintenance of tolerance in rodents and hu-
mans [2]. Several experimental models of organ-specific
autoimmune diseases provided evidence that Treg main-
tain self-tolerance and protect from the development of
autoimmune diseases [3].
In our experimental study using an anti-glomerular
basement membrane GN model [4], we demonstrated
that the transfer of Treg significantly decreased glomeru-
lar injury, reflected by decreased proteinuria and infiltra-
tion of inflammatory cells, like effector T cells, as well as
macrophages. Additionally, we provided evidence that
Treg seem to exert their immunosuppressive potential
in the draining lymph nodes of the kidneys, where the
1898
